From The Editor: ‘Tis the Season for New AD Approvals
The Dermatology Digest
DECEMBER 14, 2024
By Ted Rosen, MD Late Friday on December 13, 2024, the U.S. Food and Drug Administration approved two new therapies for atopic dermatitis (AD): Nemolizumab (Nemluvio, Galderma) and tapinarof cream, 1% (Vtama, Organon). In one day, treatment for moderate to severe AD was vastly improved. Both nemolizumab and tapinarof cream, 1% are now approved for this indication in those 12 and older and 2 and older, respectively.
36 
Let's personalize your content